Business Description
Giant Biogene Holding Co Ltd
ISIN : KYG3887G1091
Share Class Description:
HKSE:02367: Ordinary SharesCompare
Compare
Traded in other countries / regions
02367.Hong Kong IPO Date
2022-11-04Description
Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1384.64 | |||||
| Equity-to-Asset | 0.88 | |||||
| Interest Coverage | 18775.69 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 39.31 | |||||
| Beneish M-Score | -2.74 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 40.2 | |||||
| 3-Year EBITDA Growth Rate | 25.7 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 20.3 | |||||
| 3-Year Book Growth Rate | 107 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 27.46 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 33.39 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.18 | |||||
| 9-Day RSI | 46.13 | |||||
| 14-Day RSI | 44.64 | |||||
| 6-1 Month Momentum % | -9.35 | |||||
| 12-1 Month Momentum % | 11.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.79 | |||||
| Quick Ratio | 7.42 | |||||
| Cash Ratio | 7.12 | |||||
| Days Inventory | 91.7 | |||||
| Days Sales Outstanding | 6.3 | |||||
| Days Payable | 41.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.2 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| Forward Dividend Yield % | 1.2 | |||||
| 5-Year Yield-on-Cost % | 1.28 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 1.24 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.75 | |||||
| Operating Margin % | 45.84 | |||||
| Net Margin % | 39.66 | |||||
| FCF Margin % | 32.11 | |||||
| ROE % | 48.83 | |||||
| ROA % | 43.61 | |||||
| ROIC % | 213.5 | |||||
| 3-Year ROIIC % | 133.7 | |||||
| ROC (Joel Greenblatt) % | 309.63 | |||||
| ROCE % | 57.97 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.53 | |||||
| Forward PE Ratio | 14.84 | |||||
| PE Ratio without NRI | 20.81 | |||||
| Price-to-Owner-Earnings | 23.85 | |||||
| PS Ratio | 8.16 | |||||
| PB Ratio | 8.2 | |||||
| Price-to-Tangible-Book | 8.22 | |||||
| Price-to-Free-Cash-Flow | 25.05 | |||||
| Price-to-Operating-Cash-Flow | 21.63 | |||||
| EV-to-EBIT | 14.99 | |||||
| EV-to-EBITDA | 14.87 | |||||
| EV-to-Revenue | 7.15 | |||||
| EV-to-FCF | 22.69 | |||||
| Price-to-Graham-Number | 3.02 | |||||
| Price-to-Net-Current-Asset-Value | 10.14 | |||||
| Price-to-Net-Cash | 11.29 | |||||
| Earnings Yield (Greenblatt) % | 6.67 | |||||
| FCF Yield % | 3.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Giant Biogene Holding Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 4,833.241 | ||
| EPS (TTM) (HK$) | 1.941 | ||
| Beta | 0 | ||
| Volatility % | 37.87 | ||
| 14-Day RSI | 44.64 | ||
| 14-Day ATR (HK$) | 1.840184 | ||
| 20-Day SMA (HK$) | 38.7375 | ||
| 12-1 Month Momentum % | 11.49 | ||
| 52-Week Range (HK$) | 28.75 - 54.4 | ||
| Shares Outstanding (Mil) | 1,014.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Giant Biogene Holding Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Giant Biogene Holding Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Giant Biogene Holding Co Ltd Frequently Asked Questions
What is Giant Biogene Holding Co Ltd(HKSE:02367)'s stock price today?
The current price of HKSE:02367 is HK$39.85. The 52 week high of HKSE:02367 is HK$54.40 and 52 week low is HK$28.75.
When is next earnings date of Giant Biogene Holding Co Ltd(HKSE:02367)?
The next earnings date of Giant Biogene Holding Co Ltd(HKSE:02367) is .
Does Giant Biogene Holding Co Ltd(HKSE:02367) pay dividends? If so, how much?
The Dividend Yield %  of Giant Biogene Holding Co Ltd(HKSE:02367) is 1.2% (As of Today), Highest Dividend Payout Ratio of Giant Biogene Holding Co Ltd(HKSE:02367) was 0.25. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Giant Biogene Holding Co Ltd(HKSE:02367) is 1.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers